Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children’s Oncology Group

New therapeutic strategies are needed for pediatric acute myeloid leukemia (AML) to reduce disease recurrence and treatment-related morbidity. The Children's Oncology Group Phase III AAML1031 trial tested whether the addition of bortezomib to standard chemotherapy improves survival in pediatric...

Celý popis

Podrobná bibliografie

Vydáno v:	Haematologica (Roma) Ročník 105; číslo 7; s. 1879 - 1886
Hlavní autoři:	Aplenc, Richard, Meshinchi, Soheil, Sung, Lillian, Alonzo, Todd, Choi, John, Fisher, Brian, Gerbing, Robert, Hirsch, Betsy, Horton, Terzah, Kahwash, Samir, Levine, John, Loken, Michael, Brodersen, Lisa, Pollard, Jessica, Raimondi, Susana, Kolb, Edward Anders, Gamis, Alan
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Italy Ferrata Storti Foundation 01.07.2020
Témata:	Antineoplastic Combined Chemotherapy Protocols - adverse effects Bortezomib - therapeutic use Child Cytarabine - therapeutic use Disease-Free Survival Humans Leukemia, Myeloid, Acute - drug therapy Reference Standards Remission Induction Treatment Outcome
ISSN:	0390-6078, 1592-8721, 1592-8721
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!